Morales-Sandoval JJ, Téllez-Arellano CA, Fleury A

Language: Spanish
References: 20
Page: 19-27
PDF size: 338.31 Kb.

ABSTRACT

Introduction: Neurocysticercosis is a parasitosis of the central nervous system, caused by the intake of eggs from taenia solium. It has a high prevalence in certain regions of Latin America, the southeast of Asia, and sub-Saharan Africa, where unhealthy situations still prevail.
Clinical case: A 55-year-old woman with clinical symptoms of 2 years of evolution, such as recurrent headaches that had increased recently in addition to tonic-clonic seizures. In these conditions she was admitted to the hospital’s emergency department. Neuroimaging studies (tomography and magnetic resonance imaging) showed the presence of subarachnoid vesicular structures compatible with neurocysticercosis. Therefore, a cestocidal treatment was administered but the patient did not return to her follow-up appointments for 4 years. When she finally went to her appointment, she was very symptomatic and required the administration of 8 cycles of treatment to eradicate the parasites.
Discussion: The great heterogeneity and the non-specificity of the signs and symptoms difficult making a diagnosis of neurocysticercosis. Therefore, it is important to look for complementary laboratory and imaging evidence to confirm it. The treatment of neurocysticercosis represents a challenge for the physician. Particularly, when the parasite is located outside the brain parenchyma, subarachnoid cisterns and ventricular system. In less than a third of these patients the parasites disappear with a single cycle of cestocidal treatment.
Conclusion: Neurocysticercosis is a disease closely related to poverty, but it is preventable. Research focused on treatments for neurocysticercosis is still necessary.

REFERENCES

1. Carpio A, Fleury A, Romo ML, Abraham R. Neurocysticercosis: the good, the bad, and the missing. Expert Rev Neurother. 2018;18(4):289-301.

2. Delgado-García G, Méndez-Zurita VA, Bayliss L, Flores-Rivera J, Fleury A. Neurocysticercosis: mimics and chameleons. Pract Neurol. 2018;19(2):1-8.

3. Seddighi A, Nikoueia S, Sedighi A, Reza Zali A, Yourdkhani F, Tabatabaei SM, et al. Neurocysticercosis: Manifestations, Diagnosis and Treatment. International Clinical Neuroscience Journal. 2015;2(4):121-7.

4. Fleury A, Sciutto E, Larralde C. Neurocysticercosis is still prevalent in Mexico. Salud Publica Mex. 2012;54(6):632-6.

5. Torgerson PR, Devleesschauwer B, Praet N, Speybroeck N, Willingham AL, Kasuga F, et al. World Health Organization estimates of the global and regional disease bur-den of 11 foodborne parasitic diseases, 2010: a data synthesis. PLoS Med. 2015;12:1-22.

6. Murrell KD. Guidelines for the surveillance, prevention and control of taeniosis/cisticercosis. WHO/FAO/OIE, 2005; 139 pp.

7. Flisser A, Sarti E, Lightowlers M, Schantz P. Neurocysticercosis: regional status, epidemiology, impact and control measures in the Americas. Acta Tropica. 2003;87(1):43-51.

8. Bhattarai R, Carabin H, Proaño JV, Flores-Rivera J, Corona T, Flisser A, et al. e monetary burden of cysticercosis in Mexico. PLoS Negl Trop Dis. 2019;13(7):1-19.

9. Tellez-Zenteno JF, Hernandez-Ronquillo L. Epidemiology of neurocysticercosis and epilepsy, is everything described? Epilepsy Behav. 2017;76:146-50.

10. Hernández M, Astudillo OG, Diego G, de-la-Rosa-Arana JL, García-Rodea R, Romo L, et al. Immunodiagnosis of human neurocysticercosis: comparative performance of serum diagnostic tests in Mexico. Parasitol Res. 2019; 118(10):2891-9.

11. Carpio A, Fleury A, Hauser WA. Neurocysticercosis Five new things. American Academy of Neurology, Neurol Clin Pract. 2013;3(2):118-25.

12. Michelet L, Fleury A, Sciutto E, Kendjo E, Fragoso G, Paris L, et al. Human neurocysticercosis: comparison of dierent diagnostic tests using cerebrospinal tuid. J Clin Microbiol. 2011;49(1):195-200.

13. Carpio A, Fleury A, Romo ML, Abraham R, Fandiño J, Durán JC, et al. New Diagnostic Criteria for Neurocysticercosis: Reliability and Validity. Ann Neurol. 2016; 80(3):434-42.

14. Carrillo MR, Lara GJ, Arrollo M, Fleury A. Relevance of 3D magnetic resonance imaging sequences in diagnosing basal subarachnoid neurocysticercosis. Acta Trop. 2015;152:60-5.

15. Del Brutto OH, Rajshekhar V, White AC Jr, Tsang VC, Nash TE, Takayanagui OM, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57(2):177-83.

16. Garcia HH, Gonzales I, Lescano G, Bustos JA, Zimic M, Escalante D, et al. Cysticercosis Working Group in Peru. Ecacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(8):687-95.

17. Osorio R, Carillo-Mezo R, Romo ML, Toledo A, Matus C, González-Hernández I, et al. Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis. J Clin Pharmacol. 2019;59(4):548-56.

18. Toledo A, Osorio R, Matus C, Martinez-Lopez Y, Ramírez Cruz N, Sciutto E. et al. Human Extraparenchymal Neurocysticercosis: e Control of Intammation Favors the Host… but Also the Parasite. Front Immunol. 2018;16(9):2652.

19. Palomares-Alonso F, Toledo A, Palencia Hernández G, Jung-Cook H, Fleury A. Eect of dexamethasone on albendazole cysticidal activity in experimental cysticercosis by Taenia crassiceps in BALB/c mice: In vitro and in vivo evaluation. Exp Parasitol. 2020;208:107801.

20. Sciutto E, Fragoso G, Hernández M, Rosas G, Martínez JJ, Fleury A, et al. Development of the S3Pvac vaccine against porcine Taenia solium cysticercosis: a historical review. J Parasitol. 2013;99(4):686-92.